GlassScriptPhysician profile
Bassem H Rouphael
NPI 1851520381
$10,383.50
in general payments reported to CMS, 2019-2025
43 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $392 · 2021: $1,230 · 2022: $1,105 · 2023: $3,563 · 2024: $2,111 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Travel and Lodging: $3,140 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.07 |
| Travel and Lodging | $3,139.51 |
| Education | $110.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,293.52 | 2021-2024 | Ellipsys Vascular Access System |
| Bard Peripheral Vascular, INC. | $1,655.32 | 2020-2023 | Pristine |
| Astrazeneca Pharmaceuticals LP | $701.80 | 2019-2024 | Farxiga |
| Opko Pharmaceuticals, LLC | $587.05 | 2019-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $537.98 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $506.16 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $430.13 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $355.54 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $350.02 | 2019-2025 | |
| Akebia Therapeutics INC | $345.00 | 2019-2022 | |
| Vifor Pharma, INC. | $328.76 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $270.47 | 2024-2025 | |
| Glaxosmithkline, LLC. | $184.84 | 2021-2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $179.97 | 2019-2025 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $174.48 | 2022-2025 | Gattex, Livtencity |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $167.55 | 2019-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $147.94 | 2022-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $131.76 | 2022 | |
| Novo Nordisk INC | $119.66 | 2022-2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $103.05 | 2021-2022 | |
| Daiichi Sankyo INC. | $102.91 | 2019-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.75 | 2023-2025 | Jardiance |
| Amicus Therapeutics, INC. | $62.83 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $55.06 | 2025 | Yorvipath |
| Ardelyx, INC. | $51.68 | 2024-2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $41.09 | 2019-2022 | |
| Mozarc Medical US LLC | $38.65 | 2023-2024 | Chameleon |
| Boston Scientific Corporation | $38.56 | 2021 | |
| Shire North American Group INC | $34.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.94 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $30.42 | 2019 | |
| Recor Medical INC | $29.16 | 2024 | Paradise Renal Denervation System |
| Genzyme Corporation | $26.58 | 2019-2022 | |
| Becton, Dickinson and Company | $20.74 | 2024 | Lutonix Drug Coated Balloon |
| Alnylam Pharmaceuticals INC. | $20.67 | 2025 | Givlaari |
| Chiesi USA, INC. | $20.04 | 2025 | Elfabrio |
| Nxstage Medical, INC. | $16.91 | 2024 | |
| Organogenesis INC. | $16.56 | 2025 | Puraply Wound Matrix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| W. L. Gore & Associates, INC. | $15.99 | 2024 | Gore Viabahn Endoprosthesis |
| Apellis Pharmaceuticals, INC. | $15.83 | 2025 | Empaveli |
| Cormedix INC. | $14.42 | 2024 | Defencath |
| Genentech USA, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Rouphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.